HeartSciences Reports Modest Revenue Growth Amid Continued Losses in Q2 Fiscal 2026

HeartSciences Inc. reported its financial results for the second quarter of fiscal 2026, revealing a modest revenue of $2,419 for the three months ended October 31, 2025, compared to no revenue in the same period last year. For the six months ending October 31, 2025, the company generated $4,319 in revenue, marking a significant increase from zero in the prior year. Despite this revenue growth, HeartSciences continues to face substantial losses, reporting a net loss of $2.35 million for the quarter and $4.41 million for the six-month period, which reflects a slight increase in losses compared to the previous year.

The company’s total operating expenses for the quarter were $2.07 million, a 4.5% increase from $1.99 million in the same quarter of the previous year. This increase was primarily driven by a 71% rise in selling, general, and administrative expenses, which reached $1.35 million, largely due to increased stock-based compensation and personnel costs. Conversely, research and development expenses decreased by 39% to $727,026, attributed to reduced consulting costs following the completion of phase one of the MyoVista Insights platform.

HeartSciences has made strategic advancements, including the submission of its MyoVista wavECG device to the FDA for 510(k) premarket clearance in December 2025. The company has also launched the MyoVista Insights platform, which is designed to enhance ECG management and is classified as a Medical Device Data System exempt from FDA 510(k) requirements. The company is actively pursuing additional funding to support ongoing operations and product development, with a focus on regulatory clearance for its devices and algorithms.

As of October 31, 2025, HeartSciences reported total assets of $5.99 million, a significant increase from $4.22 million at the end of the previous fiscal year. The company’s cash and cash equivalents rose to $1.95 million, up from $1.1 million in April 2025. However, the company also reported an accumulated deficit of $80.5 million, raising concerns about its ability to continue as a going concern. Management has indicated that it will need to secure additional capital through equity or debt financing to sustain operations and achieve its commercialization goals.

Looking ahead, HeartSciences remains focused on advancing its product offerings and securing regulatory approvals. The company has expressed optimism about its future prospects, contingent upon successful fundraising efforts and the timely clearance of its medical devices. However, management has cautioned that the ongoing need for capital and the uncertainties surrounding regulatory processes could impact its operational viability.